References
1. Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018;384:96-103.doi:10.1016/j.jns.2017.11.022
2. Beekman J, et al. Neuromyelitis optica spectrum disorder: Patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e580. doi:10.1212/NXI.0000000000000580
3. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-783. doi:10.1002/ana.24617
4. Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-lgG-negative NMO spectrum disorder patients are MOG-lgC positive? A cross sectional study of 132 patients. J Neurol. 2017;264:2088-2094 doi:10.1007/s00415-017-8596-7
5. Horizon Therapeutics plc. NMOSD Community Satisfaction Survey. NMOSD Won’t Stop Me. 2023.